Table: Solasia Pharma -Q1 group results (IFRS)

Solasia Pharma KK

15/05/2023 07:30

May 15 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Mar 31, 2023        Mar 31, 2022     Dec 31, 2023 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              220 mln             113 mln                    
                   (+93.8 pct)         (+23.5 pct)                  
  Operating       loss 245 mln        loss 600 mln                  
  Pretax          loss 247 mln        loss 606 mln                  
  Net             loss 241 mln        loss 615 mln                  
  EPS Basic       loss 1.44 yen       loss 4.61 yen                 
  EPS Diluted     loss 1.44 yen       loss 4.61 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div                                  NIL              NIL     
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T